Table 1

Demographics and baseline characteristics

CharacteristicsPatients (N=41)
Age, years, median (range)64 (53–74)
<6521 (51.2)
≥6520 (48.8)
Sex
Male35 (85.4)
Female6 (14.6)
ECOG performance status*
05 (12.2)
135 (85.4)
Smoking status*
Never12 (29.3)
Current4 (9.8)
Former24 (58.5)
Histological type
Squamous carcinoma11 (26.8)
Non-squamous carcinoma30 (73.2)
Presence of metastases39 (95.1)
Brain metastases
Yes†1 (2.4)
No40 (97.6)
Liver metastases
Yes3 (7.3)
No38 (92.7)
Any prior antitumor treatment‡2 (4.9)
PD-L1 TPS§
1%–49%21 (51.2)
≥50%20 (48.8)
tTMB¶
Low (<10 muts/Mb)15 (36.6)
High (≥10 muts/Mb)12 (29.3)
  • Data are n (%) unless otherwise indicated.

  • *Data missing for remaining patients.

  • †One patient, who had previously experienced brain metastases and undergone whole-brain radiotherapy, demonstrated radiographic evidence of stable disease for at least 1 month and exhibited no accompanying clinical symptoms. This patient met the eligibility criteria for enrolment.

  • ‡Among the patients, one underwent curative lung cancer surgery followed by postoperative mediastinal radiotherapy and adjuvant therapy, achieving a recurrence-free interval of over 6 months post-therapy. Another patient had brain metastases and received whole-brain radiotherapy treatment.

  • §PD-L1 TPS was assessed per central laboratory testing. However, one patient was unevaluable due to the sample issues, and this patient had PD-L1 TPS of 80% per local assessment.

  • ¶Mandatory fresh biopsy or archival tissue for tTMB was not requested at enrolment.

  • ECOG, Eastern Cooperative Oncology Group; PD-L1, programmed death-ligand 1; TPS, tumor proportion score; tTMB, tissue tumor mutational burden; muts/Mb, mutations per megabase.